后腹腔镜下保留肾单位手术与肾根治切除术治疗早期肾癌的临床效果对比

Comparison of clinical effects of retroperitoneoscope nephron sparing operation and radical nephrectomy in treatment of early renal carcinoma

目的对比研究后腹腔镜下保留肾单位手术与肾根治切除术治疗早期肾癌的临床效果。方法病例样本选取时间自2018年1月起始,至2021年12月结束,回顾分析此期间于河南理工大学第一附属医院泌尿外科接受治疗的30例肾癌患者资料,依据手术方案的不同进行分组,一组为对照组(n=15),采用后腹腔镜下肾根治切除手术治疗,另一组为研究组(n=15),采用后腹腔镜下保留肾单位手术治疗,对比分析两组临床效果。结果与对照组比较,研究组的手术总时间更长(P<0.05);但研究组患者的术中出血量、术后引流量以及住院时间与对照组相比显示出更低水平(P<0.05);术后3个月、6个月,研究组的肌酐水平低于对照组(P<0.05);研究组术后各项生活质量指标评分明显高于对照组(P<0.05);术后随访1年,组间疾病复发率对比无明显差异(P>0.05)。结论相较于后腹腔镜下根治性肾切除术,保留肾单位手术用于早期肾癌治疗虽然手术时间有所增加,但可以减轻患者的手术损伤,缩短患者术后恢复时间,提升其生活质量,且复发率未增加,临床推广应用价值更高。

Objective To compare the clinical effects of retroperitoneoscope nephron sparing surgery and radical ne-phrectomy in the treatment of early renal carcinoma.Methods Case samples were selected from January 2018 to De-cember 2021,and the data of 30 patients with renal cancer who received treatment in the Department of Urology of our hospital during this period were retrospectively analyzed.The patients were divided into groups according to different sur-gical programs.One group was the control group(n=15),and the other group was the research group(n=15).Ret-roperitoneoscope nephron sparing operation was performed to compare and analyze the clinical effect of the two groups.Results Compared with the control group,the total operation time of the study group was longer(P<0.05).Howev-er,the intraoperative blood loss,postoperative drainage volume and length of hospital stay in the study group were lower than those in the control group(P<0.05).At 3 and 6 months afer surgery,the creatinine levels of the study group were lower than those the control group(P<0.05).The scores of various life quality indexes in the study group were significantly higher than those in the control group(P<0.05).After 1 year of follow-up,there was no significant difference in disease recurrence rate between groups(P>0.05).Conclusion Compared with retrolaparoscopic radical nephrectomy,nephron sparing surgery for the treatment of early renal cancer has increased the operative time,but it can reduce the surgical injury,shorten the postoperative recovery time and improve the quality of life of patients,and the re-currence rate does not increase,so it has higher clinical application value.